S&P・Nasdaq 本質的価値 お問い合わせ

Bone Biologics Corporation BBLG NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Bone Biologics Corporation (BBLG) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.

アナリスト予想 一株当たり利益(EPS) $-19.02 および 売上高 $0.00B 来期予想.

一株当たり利益(EPS)実績推移: 2024: 実績 $-4.83 vs 予想 $-19.02 (上回る +74.6%). 2025: 実績 $-2.65 vs 予想 $-2.36 (下回る -12.3%). アナリスト精度: 0%.

EPS予測 — BBLG

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$4.83 vs Est –$19.02 ▲ 293.8% off
2025 Actual –$2.65 vs Est –$2.36 ▼ 10.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

売上高予測 — BBLG

Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
お問い合わせ
🎓
SharesGrow アカデミー
本質的価値の計算と割安株の見つけ方を学ぶ。
毎週のライブセッション
メッセージを送る